Response to Letter to the Editor from Chatelain et al.: Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial
Response to Letter to the Editor from Chatelain et al.: Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial / Miller, B.S., Blair, J.C., Rasmussen, M.H., Maniatis, A., Kildemoes, R.J., Mori, J., Polak, M., Bang, R.B., Böttcher, V., Stagi, S., Horikawa, R.. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - ELETTRONICO. - (2023), pp. 0-0. [10.1210/clinem/dgad095]
Response to Letter to the Editor from Chatelain et al.: Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial
Stagi, Stefano;
2023
Abstract
Response to Letter to the Editor from Chatelain et al.: Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial
| File | Dimensione | Formato | |
|---|---|---|---|
|
dgad095.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
201.76 kB
Formato
Adobe PDF
|
201.76 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
